QLGN Profile
Qualigen Therapeutics, Inc. is a biotechnology firm dedicated to advancing novel therapeutic solutions for cancer and infectious diseases. The company is recognized for its innovative approach to both drug development and diagnostic testing. Qualigen's product lineup includes FastPack, a rapid diagnostic testing system designed to provide quick and accurate results in clinical settings. This system is integral to the company's diagnostic offerings and supports its broader mission of enhancing patient care through timely and precise diagnostics.
The company's drug development pipeline features several promising candidates targeting various cancer types. QN-302 is in development for the treatment of pancreatic ductal adenocarcinoma, a particularly aggressive form of cancer. QN-247 represents another key candidate, utilizing DNA-coated gold nanoparticles to target and treat a range of cancers. Additionally, RAS-F, a small-molecule inhibitor, aims to disrupt RAS oncogene protein interactions, thereby blocking RAS mutations that are critical to tumor formation and progression.
Qualigen is also advancing the STARS blood cleansing system, a pioneering treatment device designed to purify a patient’s blood by removing tumor-produced compounds and viruses. This DNA/RNA-based technology represents a novel approach to treating cancer and improving patient outcomes by addressing tumor-related toxins and pathogens directly in the bloodstream.
Founded in 1996 and headquartered in Carlsbad, California, Qualigen Therapeutics is committed to leveraging cutting-edge science and technology to address unmet medical needs. The company's ongoing research and development efforts reflect its dedication to innovation in both therapeutic and diagnostic fields, positioning it as a significant player in the biotechnology sector. With a focus on delivering effective solutions for challenging medical conditions, Qualigen continues to push the boundaries of what's possible in patient care.
|
